DELCATH SYSTEMS, INC. (DCTH)
$16.35-$0.05 (-0.31%) Today
Latest DCTH Insider Trades
Sandra Pennell - OfficerOpen-market purchase$50K
Sandra Pennell - Officer
Bridget A. MartellDelcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
No Form 4 activity for DCTH in the last 90 days.
23 Form 4 filings on record, the earliest from Oct 23, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| John Richard Sylvester | Grant or award | Stock Option (right to buy) | 22,500 | $0.00 | - | |
| Bridget A. Martell | Grant or award | Stock Option (right to buy) | 22,500 | $0.00 | - | |
| Elizabeth Czerepak | Grant or award | Stock Option (right to buy) | 22,500 | $0.00 | - | |
| Steven A. J. Salamon | Grant or award | Stock Option (right to buy) | 22,500 | $0.00 | - | |
| Gil Aharon | Grant or award | Stock Option (right to buy) | 22,500 | $0.00 | - | |
| Sandra Pennell - Officer | Open-market purchase | Common Stock | 5,533 | $9.04 | $50K | |
| Gerard J. Michel - Officer | Open-market purchase | Common Stock | 11,200 | $8.96 | $100K | |
| David L. Hoffman - Officer | Grant or award | Stock Option (Right to Buy) | 56,500 | $0.00 | - | |
| David L. Hoffman - Officer | Grant or award | Restricted Stock Units | 28,250 | $0.00 | - | |
| Kevin Muir - Officer | Grant or award | Stock Option (Right to Buy) | 56,500 | $0.00 | - | |
| Kevin Muir - Officer | Grant or award | Restricted Stock Units | 28,250 | $0.00 | - | |
| Sandra Pennell - Officer | Grant or award | Stock Option (Right to Buy) | 56,500 | $0.00 | - | |
| Sandra Pennell - Officer | Grant or award | Restricted Stock Units | 28,250 | $0.00 | - | |
| Vojo Vukovic - Officer | Grant or award | Stock Option (Right to Buy) | 56,500 | $0.00 | - | |
| Vojo Vukovic - Officer | Grant or award | Restricted Stock Units | 28,250 | $0.00 | - | |
 Martha S. Rook - Officer | Grant or award | Stock Option (Right to Buy) | 56,500 | $0.00 | - | |
| Martha S. Rook - Officer | Grant or award | Restricted Stock Units | 28,250 | $0.00 | - | |
| Gerard J. Michel - Officer | Grant or award | Stock Option (Right to Buy) | 195,000 | $0.00 | - | |
| Gerard J. Michel - Officer | Grant or award | Restricted Stock Units | 97,500 | $0.00 | - | |
| John Richard Sylvester | Open-market purchase | Common Stock | 4,386 | $8.89 | $39K | |
| Gerard J. Michel - Officer | Open-market purchase | Common Stock | 11,500 | $8.53 | $98K | |
| Elizabeth Czerepak | Grant or award | Stock Option (right to buy) | 22,500 | $0.00 | - | |
| Steven A. J. Salamon - Director | Other | Common shares | 250,000 | $10.00 | $2.50M | |
| Steven A. J. Salamon - Director | Option exercise | Pre-funded Warrants | 603,954 | $9.99 | $6.03M | |
| Gil Aharon - Director | Other | Common shares | 250,000 | $10.00 | $2.50M | |
| Gil Aharon - Director | Option exercise | Pre-funded Warrants | 603,954 | $9.99 | $6.03M | |
| Rosalind Advisors, Inc. - Director | Other | Common shares | 250,000 | $10.00 | $2.50M | |
| Rosalind Advisors, Inc. - Director | Option exercise | Pre-funded Warrants | 603,954 | $9.99 | $6.03M | |
| Gil Aharon - Director | Option exercise | Tranche B warrants to purchase F-4 Preferred Stock | 500 | $1,000.00 | $500K | |
| Gil Aharon - Director | Other | 8% CONVERTIBLE NOTE | 0 | $0.00 | - | |
| Steven A. J. Salamon - Director | Option exercise | Tranche B warrants to purchase F-4 Preferred Stock | 500 | $1,000.00 | $500K | |
| Steven A. J. Salamon - Director | Other | 8% CONVERTIBLE NOTE | 0 | $0.00 | - | |
| Rosalind Advisors, Inc. - Director | Option exercise | Tranche B warrants to purchase F-4 Preferred Stock | 500 | $1,000.00 | $500K | |
| Rosalind Advisors, Inc. - Director | Other | 8% CONVERTIBLE NOTE | 0 | $0.00 | - | |
| Gerard J. Michel - Officer | Option exercise | Common Stock | 16,666 | $6.00 | $100K | |
| Gerard J. Michel - Officer | Option exercise | Tranche B Warrants to Purchase Common Stock | 16,666 | $0.13 | $2K |
DELCATH SYSTEMS, INC. (DCTH) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-05-14. The full record for DCTH runs to 23 Form 4 filings, the earliest from 2024-10-23. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of DCTH were filed in the last 90 days. 4 purchases are on record for this company.
No insider sales of DCTH were filed in the last 90 days.
This page tracks DCTH Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add DCTH to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
